Jim Birchenough
Stock Analyst at Wells Fargo
(2.89)
# 1,494
Out of 5,178 analysts
29
Total ratings
57.89%
Success rate
38.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.34 | +481.23% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $47.55 | +47.21% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $24.69 | +94.41% | 3 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.23 | +10,469.11% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $3.89 | +259.90% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $53.57 | +170.67% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $136.88 | -53.97% | 5 | Oct 29, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $15.60 | +258.97% | 3 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | $734 | $756.73 | -3.00% | 2 | May 26, 2020 | |
| KZR Kezar Life Sciences | Maintains: Overweight | $300 → $180 | $6.35 | +2,734.65% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $7.28 | +353.30% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.34
Upside: +481.23%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $47.55
Upside: +47.21%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $24.69
Upside: +94.41%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.23
Upside: +10,469.11%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $3.89
Upside: +259.90%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $53.57
Upside: +170.67%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $136.88
Upside: -53.97%
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $15.60
Upside: +258.97%
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $756.73
Upside: -3.00%
Kezar Life Sciences
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $6.35
Upside: +2,734.65%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $7.28
Upside: +353.30%